We found that combination of doxorubicin chemotherapy and Apo2L/TRAIL is more effective in tumor growth inhibition than either agent alone, indicating that this may represent a novel treatment strategy against prostate cancer. This evidence concerns the gene TNFSF10 and prostate cancer.